Akero Therapeutics Inc (STU:0K4)
€ 28.54 -0.79 (-2.69%) Market Cap: 2.03 Bil Enterprise Value: 1.38 Bil PE Ratio: 0 PB Ratio: 2.89 GF Score: 34/100

Akero Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2020 / 06:15PM GMT
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Hey, folks. I'm Tiago Fauth, biotech analyst here at Crédit Suisse. I just want to welcome the Akero Therapeutics team for a presentation this afternoon. We have Tim. So yes, you guys can take it away.

Timothy Rolph
Akero Therapeutics, Inc. - Co-Founder & Chief Scientific Officer

Good afternoon, good morning, and welcome to the Akero presentation. My name is Tim Rolph. I'm the Chief Scientific Officer and 1 of the 2 Co-Founders of Akero. Today's presentation will focus on the clinical data we generated earlier this year in our BALANCED study in biopsy-proven NASH. And these are the highlights that I'm going to talk about during the course of this presentation. We saw very substantial improvements in terms of reducing liver fat, ranging from amongst the highest to the highest reported. We saw a substantial reduction in liver injury, indicated by 40% reduction in liver enzyme activity levels. And we saw encouraging signs based on ELF and Pro-C3 that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot